Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2461 to 2475 of 7710 results

  1. Relugolix–estradiol–norethisterone for treating symptoms of endometriosis [ID3982]

    In development [GID-TA10873] Expected publication date: 16 April 2025

    Technology appraisal guidance
    In development

  2. Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]

    In development [GID-TA11288] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  3. Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]

    In development [GID-TA11423] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment

    In development [GID-HTE10056] Expected publication date: 24 April 2025

    Health technology evaluations
    In development

  5. Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]

    In development [GID-TA10571] Expected publication date: 22 May 2025

    Technology appraisal guidance
    In development

  6. Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]

    In development [GID-TA11570] Expected publication date: 24 July 2025

    Technology appraisal guidance
    In development

  7. Robot-assisted surgery for soft-tissue procedures: early value assessment

    In development [GID-HTE10040] Expected publication date: 31 March 2025

    Health technology evaluations
    In development

  8. Molnupiravir for treating COVID-19 [ID6340]

    In development [GID-TA11409] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]

    Awaiting development [GID-TA11511] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma [ID4044]

    In development [GID-TA10930] Expected publication date: 28 May 2025

    Technology appraisal guidance
    In development

  11. Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]

    In development [GID-TA10977] Expected publication date: 16 July 2025

    Technology appraisal guidance
    In development

  12. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]

    In development [GID-TA10979] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]

    In development [GID-TA11228] Expected publication date: 11 June 2025

    Technology appraisal guidance
    In development

  14. Depemokimab for treating severe eosinophilic asthma in people 12 years and over ID6447

    Awaiting development [GID-TA11553] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]

    In development [GID-TA11355] Expected publication date: 12 February 2025

    Technology appraisal guidance
    In development